На главную
Результаты поиска “Endostatin for dog cancer”
English/Nat The U-S drug company which has developed a promising cancer treatment in mice has more than quadrupled in value over the past couple of days. While EntreMed's treatment is not ready for human trials, other companies have already begun testing similar drugs in patients. Researchers are warning that optimism over the drugs' success in mice should be tempered with caution because drugs tested in animals often do not work on humans. In some reports, EntreMed's new treatment has been heralded as the new hope that a cure may be found for cancer. But scientists at the Maryland-based drug company that developed the drugs endostatin and angiostatin, say that such talk is far too premature. The compounds were very successful in treating various forms of cancer in laboratory mice. But cancer in mice is far easier to treat than cancer in people. And scientists warn that breakthroughs from animal testing rarely translate into significant new treatments in human beings. The Chairman and Chief Executive Officer of EntreMed says this must not be seen as a miracle cure. SOUNDBITE: (English) "I think it's definitely too early to call it that. I think what we can do is what Dr Folkman would say and that is if you're a mouse and you have cancer we can cure you. But there's a long way between mouse and man and we must be very aware of the hurdles we face in developing a new drug. We also must be aware of the fact we're being asked to do it faster than anyone has ever done it before. I think we're up to that challenge." SUPER CAPTION: Dr. John Holaday, Chairman and Chief Executive Officer of EntreMed Researchers are hoping that the differences with the way angiostatin and endostatin work may lead the way to a successful treatment. The drugs inhibit the development of new blood vessels in tumours rather than attacking the cancer cells themselves. The University of California at Los Angeles Medical Center is beginning a trial of a drug similar to angiostatin and endostatin called SU5416. After years of chemotherapy and other traumatic treatments, Scott Campbell says he is impressed with the new drug. SOUNDBITE: (English) "Well I'm very hopeful only because I know how I feel and over the last five or six months the way that I feel is so much better than I've ever felt before." SUPER CAPTION: Scott Campbell, Cancer Patient SU5416 is one of several others drugs aimed at blocking blood vessels that have already entered early stages of human testing. Researchers said there are perhaps 50 in all in various stages of development. Unlike previous drugs, they cut off the blood supply to the tumour whereas chemotherapy and radiation attack the cancerous cells themselves. SOUNDBITE: (English) "The tumour will create tons of new blood vessels to itself and the theory goes that if you can cut out that blood vessel formation the tumour will stop growing or perhaps it will stop spreading or maybe it will go away completely." SUPER CAPTION: Dr. Lee Rosen, Director of Cancer Treatment Program Although the treatment has been described as a miracle cure, researchers warn that it's far too early to make that assumption. SOUNDBITE:(English) "Though I'm very excited about this as a new class of drugs it's by no means the miracle cure or the thing that's going to be making cancer go away, I mean we should all be so lucky to have that first patient whose tumour goes away completely or who derives some benefit or quality of life before we use the words 'miracle cure.' SUPER CAPTION: Dr Lee Rosen, Director of Cancer Treatment Program Engiostatin and endostatin trials on humans will not begin for at least a year. Similar drug trials such as the one for SU5416 are already underway and looking to sign up new patients. You can license this story through AP Archive: http://www.aparchive.com/metadata/youtube/1f08c69726c7b61d9659afffcb38772a Find out more about AP Archive: http://www.aparchive.com/HowWeWork
Просмотров: 86 AP Archive
Cancer Warrior
Dr. Judah Folkman's pioneering cancer research.
Просмотров: 1190 Pete VanDemark
Ophthalmic Genetics and Clinical Treatment Opportunities - Paul Sieving
February 8, 2013 - Genomics in Medicine Lecture Series More: http://www.genome.gov/27549874
Просмотров: 963 National Human Genome Research Institute
turgut özal üniversitesi hemodiyaliz hastalarında akustik immitasmetri ve otoakustik emisyon değerle
Tuğçe Sıla Baytok , Merve Yılmaz , Nuray Zenginer , Tuğba Tükenmez , Hilal Köse , Burcu İşcan , Simge Aydın , Eser Sendesen , Soner Türüdü , Asuman Erdoğan , Ayşegül Taşkın
Просмотров: 297 tobat kongre